China has wrapped up a 10-month bribery investigation into pharmaceutical giant GlaxoSmithKline’s operations there, resulting in bribery charges against the former head of GSK China, according to Chinese law enforcement and published reports.
Mark Reilly, a British national who served as managing director of GSK China, is accused of ordering subordinates to commit bribery in order to boost drug sales for the U.K.-based company, according to the official Chinese news service Xinhua. Xinhua reported that law enforcement officials had finished a 10-month bribery investigation involving GSK, and found that Reilly allegedly pressed his sales teams to bribe hospitals, doctors, and other health-care institutions, resulting in billions of yuan in increased revenue.
